

CITATION REPORT

List of articles citing

Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation

DOI: 10.1046/j.0022-3042.2001.00728.x

Journal of Neurochemistry, 2002, 80, 589-97.

Source: <https://exaly.com/paper-pdf/34592260/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
281	Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. 2002 , 16, 669-94		463
280	Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. 2002 , 43, 1173-9		206
279	Molecular Mechanisms of Action of Mood Stabilizers in Bipolar Disorder. 2002 , 21, 112-136		1
278	Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. 2002 , 96, 45-66		133
277	Mood stabilizer psychopharmacology. 2002 , 2, 193-212		47
276	Long-term lithium treatment prevents neurotoxic effects of beta-bungarotoxin in primary cultured neurons. 2002 , 69, 633-41		22
275	Neuroprotective effects of lithium in cultured cells and animal models of diseases. 2002 , 4, 129-36		190
274	Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. 2003 , 1003, 273-91		143
273	The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. 2003 , 97, 55-85		298
272	Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. <i>Journal of Neurochemistry</i> , 2003 , 84, 566-75	6	121
271	Molecular targets of lithium action. 2003 , 15, 316-40		23
270	Drug research: the ups and downs of lithium. 2003 , 425, 118-20		79
269	Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. 2003 , 34, 1287-92		133
268	Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity. 2003 , 538, 145-8		54
267	Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. 2003 , 542, 74-8		98
266	Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. 2003 , 53, 707-42		412
265	Lithium reduced N-methyl-D-aspartate receptor subunit 2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by PSD-95 in rat hippocampus following cerebral ischemia. 2003 , 348, 185-9		48

264	The effect of lithium on expression of genes for inositol biosynthetic enzymes in mouse hippocampus; a comparison with the yeast model. 2003 , 115, 104-10		32
263	Lithium stimulates progenitor proliferation in cultured brain neurons. 2003 , 117, 55-61		80
262	Attenuation of N-methyl-D-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers. 2003 , 117, 949-55		35
261	Features of the comparative pharmacokinetics of lithium; a potential application of its use in livestock farming. 2003 , 61, 278-81		7
260	Lithium chloride, administered chronically to rats, does not affect the fractional phosphorylation of brain cytosolic phospholipase A2, while reducing its net protein level. 2003 , 59, 303-6		9
259	Predicting response to lithium in mood disorders: role of genetic polymorphisms. 2003 , 3, 17-30		21
258	Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. 2003 , 100, 6210-5		173
257	Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. <i>Pharmacopsychiatry</i> , 2003 , 36 Suppl 3, S250-4	2	52
256	Treatment models and designs for intervention research during the psychotic prodrome. 2003 , 29, 747-56		15
255	Selective activation induced cleavage of the NR2B subunit by calpain. 2003 , 23, 11322-31		117
254	Chronic lithium treatment attenuates intracellular calcium mobilization. 2004 , 29, 759-69		66
253	Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamus in Schizophrenia and Bipolar Disorder. 2004 , 29, 1353-62		135
252	Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. <i>Journal of Neurochemistry</i> , 2004 , 89, 1358-67	6	317
251	Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. 2004 , 9, 371-85		84
250	Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. 2004 , 9, 734-55		204
249	Chronic lithium treatment of B lymphoblasts from bipolar disorder patients reduces transient receptor potential channel 3 levels. 2004 , 4, 365-73		32
248	Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high-affinity glutamate uptake. 2004 , 24, 1226-34		46
247	Neurotrophic signaling cascades are major long-term targets for lithium: clinical implications. 2004 , 4, 137-153		8

246	Regulation of molecular chaperone GRP78 by mood stabilizing drugs. 2004 , 4, 281-288		5
245	Lithium protection from glutamate excitotoxicity: therapeutic implications. 2004 , 4, 243-252		8
244	Inactivation of glycogen synthase kinase-3beta protects against kainic acid-induced neurotoxicity in vivo. <i>Brain Research</i> , 2004 , 1026, 116-25	3.7	31
243	Valproate modulates TRH receptor, TRH and TRH-like peptide levels in rat brain. 2004 , 25, 647-58		27
242	Lithium suppressed Tyr-402 phosphorylation of proline-rich tyrosine kinase (Pyk2) and interactions of Pyk2 and PSD-95 with NR2A in rat hippocampus following cerebral ischemia. 2004 , 49, 357-62		31
241	Neuronal Energy Metabolism in Brain: Astrocyte as both Metabolic Buffer and Mediator of Neuronal Injury. 2004 , 277-302		
240	Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. 2005 , 99, 307-21		127
239	Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. 2005 , 32, 173-202		123
238	Changes in phosphorylation of the NMDA receptor in the rat hippocampus induced by status epilepticus. <i>Journal of Neurochemistry</i> , 2005 , 92, 1377-85	6	32
237	Effects of intraperitoneally injected lithium, imipramine and diazepam on nitrate levels in rat amygdala. 2005 , 59, 358-61		27
236	Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2. 2005 , 5, 102-11		86
235	Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against beta-amyloid peptide neurotoxicity. 2005 , 40, 716-27		170
234	Isoflurane and sevoflurane affect cell survival and BCL-2/BAX ratio differently. <i>Brain Research</i> , 2005 , 1037, 139-47	3.7	163
233	Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. 2005 , 25, 2647-57		115
232	Enhancing resilience to stress: the role of signaling cascades. 2005 , 751-771		1
231	Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant?. 2005 , 28, 399-414		10
230	Effects of chemical ischemia in cerebral cortex slices. Focus on nitric oxide. 2005 , 47, 482-90		13
229	The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. 2005 , 47, 845-57		301

228	GABA and glutamate systems as therapeutic targets in depression and mood disorders. 2005 , 9, 153-68		112
227	The breakpoint cluster region gene on chromosome 22q11 is associated with bipolar disorder. 2005 , 57, 1097-102		33
226	Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. 2005 , 58, 879-84		171
225	Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. 2006 , 78, 1317-23		75
224	Differential expression of the NMDA NR2B receptor subunit in motoneuron populations susceptible and resistant to amyotrophic lateral sclerosis. 2006 , 399, 157-61		13
223	A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. 2006 , 9, 83-8		42
222	Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. 2006 , 11, 1116-25		282
221	Advances in the treatment of anxiety: targeting glutamate. 2006 , 3, 57-68		45
220	U18666A-mediated apoptosis in cultured murine cortical neurons: role of caspases, calpains and kinases. 2006 , 18, 1572-83		19
219	Cytoprotection by lithium and valproate varies between cell types and cellular stresses. 2006 , 539, 18-26		92
218	Enhancement of neuroprotection and heat shock protein induction by combined prostaglandin A1 and lithium in rodent models of focal ischemia. <i>Brain Research</i> , 2006 , 1102, 154-62	3-7	38
217	Brain-derived neurotrophic factor rapidly increases NMDA receptor channel activity through Fyn-mediated phosphorylation. <i>Brain Research</i> , 2006 , 1121, 22-34	3-7	82
216	Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. 2006 , 31, 1659-74		92
215	Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. 2006 , 26, 7502-12		161
214	Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. 2006 , 281, 30479-84		99
213	Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. 2007 , 14, 2799-812		38
212	Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. 2007 , 282, 3904-17		111
211	Stage II follow-up on a linkage scan for bipolar disorder in the Ashkenazim provides suggestive evidence for chromosome 12p and the GRIN2B gene. 2007 , 9, 745-51		28

210	Neurocognitive impairment and dementia in mood disorders. 2007 , 19, 373-82		21
209	Lithium inhibits function of voltage-dependent sodium channels and catecholamine secretion independent of glycogen synthase kinase-3 in adrenal chromaffin cells. 2007 , 53, 881-9		34
208	In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked?. 2007 , 62, 4-6		54
207	Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2. <i>Journal of Neurochemistry</i> , 2007 , 102, 1918-1927	6	49
206	Lithium reduces ischemia-induced hippocampal CA1 damage and behavioral deficits in gerbils. <i>Brain Research</i> , 2007 , 1184, 270-6	3.7	65
205	Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. <i>Neurobiology of Disease</i> , 2007 , 26, 464-72	7.5	151
204	Lithium and valproate protect hippocampal slices against ATP-induced cell death. <i>Neurochemical Research</i> , 2007 , 32, 1539-46	4.6	11
203	Early intervention in bipolar disorder, part II: therapeutics. 2008 , 2, 136-46		16
202	Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. 2008 , 7, 426-37		633
201	The Antiapoptotic Actions of Mood Stabilizers. 2008 , 1053, 195-204		2
200	Neuroprotective effect of chronic lithium treatment against hypoxia in specific brain regions with upregulation of cAMP response element binding protein and brain-derived neurotrophic factor but not nerve growth factor: comparison with acute lithium treatment. 2008 , 10, 360-8		29
199	Lithium-induced suppression of transcription repressor NRSF/REST: effects on the dysfunction of neuronal differentiation by ethanol. 2008 , 593, 36-43		19
198	Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. 2008 , 29, 1631-43		21
197	Lithium effects on brain glutamatergic and GABAergic systems of healthy volunteers as measured by proton magnetic resonance spectroscopy. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008 , 32, 249-56	5.5	33
196	Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. 2008 , 28, 2576-88		187
195	Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. 2008 , 33, 2551-65		122
194	A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic?. 2008 , 11, 269-87		59
193	Family-based association study of lithium-related and other candidate genes in bipolar disorder. 2008 , 65, 53-61		52

192	Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. 2008 , 9, 1595-603		67
191	Neurodegeneration and neuroprotective agents in multiple sclerosis. 2008 , 3, 153-65		6
190	No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. <i>PLoS ONE</i> , 2009 , 4, e6489	3.7	69
189	Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. 2009 , 2, 95-109		172
188	Glycogen synthase kinase-3/Shaggy mediates ethanol-induced excitotoxic cell death of <i>Drosophila</i> olfactory neurons. 2009 , 106, 20924-9		32
187	The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. 2009 , 15, 525-39		132
186	Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. 2009 , 94, 148-53		73
185	Estradiol and lithium chloride specifically alter NMDA receptor subunit NR1 mRNA and excitotoxicity in primary cultures. <i>Brain Research</i> , 2009 , 1268, 1-12	3.7	14
184	The association study of three FYN polymorphisms with prophylactic lithium response in bipolar patients. 2009 , 24, 287-91		25
183	The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. 2009 , 11 Suppl 2, 92-109		229
182	Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. <i>Journal of Neurochemistry</i> , 2009 , 111, 976-87	6	115
181	Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. 2009 , 15, 176-86		67
180	A role for nitrenergic system in the antidepressant-like effects of chronic lithium treatment in the mouse forced swimming test. 2009 , 200, 76-82		42
179	Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro. 2009 , 56, 422-8		32
178	Lithium treatment prevents stress-induced dendritic remodeling in the rodent amygdala. 2009 , 163, 34-9		46
177	No association of three GRIN2B polymorphisms with lithium response in bipolar patients. 2009 , 61, 448-52		23
176	Lower serum levels of lithium may produce efficacy without adverse effects. 2009 , 17, 625; author reply 625-6		1
175	Authors Respond to Letter, Lower Serum Levels of Lithium may Produce Efficacy Without Adverse Effects 2009 , 17, 625-626		0

174	Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium. 2009 , 10, 433-47	30
173	Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. 2009 , 15, 1595-611	96
172	Intracellular pathways underlying the effects of lithium. 2010 , 21, 473-92	83
171	Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. 2010 , 128, 281-304	166
170	The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat. 2010 , 641, 193-8	21
169	Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. 2010 , 14, 354-9	37
168	Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Aβ peptide. Implications for the pathogenesis of Alzheimer's disease. 2010 , 5, 4	80
167	Research in people with psychosis risk syndrome: a review of the current evidence and future directions. 2010 , 51, 390-431	136
166	Searching susceptibility loci for bipolar disorder: a sib pair study on chromosome 12. <i>Neuropsychobiology</i> , 2010 , 61, 10-8	4 5
165	Glutamatergic modulators: the future of treating mood disorders?. 2010 , 18, 293-303	168
164	Anaesthetic implications of psychoactive drugs. 2010 , 10, 177-181	15
163	Neuroprotection by valproic Acid in mouse models of permanent and transient focal cerebral ischemia. 2010 , 14, 435-40	30
162	Lithium prevents excitotoxic cell death of motoneurons in organotypic slice cultures of spinal cord. 2010 , 165, 1353-69	50
161	Voltage-dependent calcium channel and NMDA receptor antagonists augment anticonvulsant effects of lithium chloride on pentylentetrazole-induced clonic seizures in mice. 2010 , 18, 171-8	29
160	NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. 2010 , 24, 585-94	65
159	Neuroprotection in Bipolar Depression. 2010 , 451-483	0
158	The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. 2011 , 32, 420-34	53
157	Urocortin modulates dopaminergic neuronal survival via inhibition of glycogen synthase kinase-3β and histone deacetylase. 2011 , 32, 1662-77	16

156	Memantine reduces mania-like symptoms in animal models. 2011 , 188, 366-71		24
155	Involvement of the glycogen synthase kinase-3 signaling pathway in TBI pathology and neurocognitive outcome. <i>PLoS ONE</i> , 2011 , 6, e24648	3-7	61
154	Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31]. 2011 , 11, 111		14
153	Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. 2011 , 28, 267-81		20
152	Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. 2011 , 32, 1433-45		37
151	GSK-3 as a Target for Lithium-Induced Neuroprotection Against Excitotoxicity in Neuronal Cultures and Animal Models of Ischemic Stroke. 2011 , 4, 15		116
150	Advances in neuroprotective strategies: potential therapies for intracerebral hemorrhage. 2011 , 31, 211-22		97
149	Lithium and its neuroprotective and neurotrophic effects: potential treatment for post-ischemic stroke sequelae. 2011 , 12, 243-55		34
148	Lithium/nutrition interaction in the brain: a single lithium administration impairs spreading depression in malnourished, but not in well-nourished rats. 2011 , 14, 159-64		4
147	Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways. 2011 , 8, 210-8		17
146	Lithium citrate as treatment of Canavan disease. 2012 , 35, 150-1		8
145	Nitroergic, glutamatergic and gabaergic systems in lithium toxicity. 2012 , 37, 1017-23		3
144	P.2.f.001 Effects of chronic lithium treatment on long-term potentiation and some behavioral tests in adult rats. 2012 , 22, S292-S293		
143	P.2.f.002 The effect of lithium on brain inositol turnover. 2012 , 22, S293		
142	P.2.f.003 Acute and repeated ketamine treatment leads to biphasic effects in the DRL72 test, a model for depression in rats. 2012 , 22, S293-S294		
141	Evaluation of the antiepileptic effect of curcumin and Nigella sativa oil in the pilocarpine model of epilepsy in comparison with valproate. 2012 , 24, 199-206		31
140	Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. 2012 , 229, 208-15		58
139	Divergent effects of lithium and sodium valproate on brain-derived neurotrophic factor (BDNF) production in human astrocytoma cells at therapeutic concentrations. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012 , 39, 17-22	5-5	18

138	A new trick of INPP4A: decreased expression of INPP4A in patients with temporal lobe epilepsy and pilocarpine-induced rat model. 2012 , 66, 533-41	5
137	Lithium attenuates peripheral neuropathy induced by paclitaxel in rats. 2012 , 110, 231-7	24
136	Novel glutamatergic agents for major depressive disorder and bipolar disorder. 2012 , 100, 678-87	65
135	Lithium: Molecular interactions, clinical actions. 2012 , 3,	2
134	Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. 2012 , 14, 478-87	151
133	Neuroprotective effects of lithium treatment following hypoxic-ischemic brain injury in neonatal rats. 2012 , 28, 191-8	14
132	Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy. 2013 , 250, 417-33	8
131	Study of morphological changes of neuroblastoma cells induced by activation of NMDA receptor. 2013 ,	
130	Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. 2013 , 65, 105-42	293
129	Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. 2013 , 38, 468-75	58
128	Lithium in patients with amyotrophic lateral sclerosis (LiALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. 2013 , 12, 339-45	94
127	Neuroprotective effects of Polygonum multiflorum extract against glutamate-induced oxidative toxicity in HT22 hippocampal cells. 2013 , 150, 108-15	23
126	Epigenetic mechanisms in cerebral ischemia. 2013 , 33, 1335-46	75
125	Neuroprotective effects of chronic exposure of SH-SY5Y to low lithium concentration involve glycolysis stimulation, extracellular pyruvate accumulation and resistance to oxidative stress. 2013 , 16, 365-76	30
124	GRIN2B gene and associated brain cortical white matter changes in bipolar disorder: a preliminary combined platform investigation. <i>BioMed Research International</i> , 2013 , 2013, 635131	3 5
123	Investigation of N-methyl-D-aspartate induced mechanical behavior of neuroblastoma cells using atomic force microscopy. 2013 ,	
122	Lithium's role in neural plasticity and its implications for mood disorders. 2013 , 128, 347-61	32
121	NR2B subunit of the NMDA glutamate receptor regulates appetite in the parabrachial nucleus. 2013 , 110, 14765-70	28

120	Inhibition of glycogen synthase kinase-3 β prevents remifentanyl-induced hyperalgesia via regulating the expression and function of spinal N-methyl-D-aspartate receptors in vivo and vitro. <i>PLoS ONE</i> , 2013 , 8, e77790	3-7	28
119	Chronic treatment with mood-stabilizers attenuates abnormal hyperlocomotion of GluA1-subunit deficient mice. <i>PLoS ONE</i> , 2014 , 9, e100188	3-7	25
118	Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?. 2014 , 10, 1024-38		33
117	The effect of lithium in post-stroke motor recovery: a double-blind, placebo-controlled, randomized clinical trial. 2014 , 37, 73-8		30
116	Effects of lithium and aripiprazole on brain stimulation reward and neuroplasticity markers in the limbic forebrain. 2014 , 24, 630-8		5
115	Molecular actions and clinical pharmacogenetics of lithium therapy. 2014 , 123, 3-16		76
114	Prolonged peripheral nerve blockade in patients using lithium carbonate. 2014 , 42, e33-5		1
113	Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPAR α and HDAC pathways. 2014 , 26, 130-51		19
112	The theory of bipolar disorder as an illness of accelerated aging: implications for clinical care and research. 2014 , 42, 157-69		105
111	Calcium dysregulation, and lithium treatment to forestall Alzheimer's disease - a merging of hypotheses. 2014 , 55, 175-81		16
110	Activity-dependent regulation of NMDA receptors in substantia nigra dopaminergic neurones. 2014 , 592, 653-68		12
109	The emerging role of dopamine-glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment. 2014 , 28, 505-26		32
108	Standard and trace-dose lithium: a systematic review of dementia prevention and other behavioral benefits. 2014 , 48, 809-18		27
107	P.1.i.006 Brain white matter connectivity associated with treatment response to paliperidone ER treatment in patients with schizophrenia. 2014 , 24, S299-S300		
106	Lithium/Valproic acid combination and L-glutamate induce similar pattern of changes in the expression of miR-30a-5p in SH-SY5Y neuroblastoma cells. 2014 , 16, 872-7		6
105	A new avenue for lithium: intervention in traumatic brain injury. 2014 , 5, 422-33		72
104	The role of NMDA receptors in the pathophysiology and treatment of mood disorders. 2014 , 47, 336-58		73
103	P.1.i.005 Prefrontal cortex gamma-aminobutyric acid levels in bipolar I disorder determined using proton magnetic resonance spectroscopy. 2014 , 24, S299		

102	P.1.i.004 Resting-state functional connectivity in temporal lobe epilepsy patients with affective symptoms. 2014 , 24, S298-S299		
101	Effects of lithium and valproic acid on BDNF protein and gene expression in an in vitro human neuron-like model of degeneration. 2014 , 28, 964-72		18
100	Lithium Pharmacology. 2015 , 1-9		
99	Antidepressant mechanism of ketamine: perspective from preclinical studies. 2015 , 9, 249		39
98	Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2015 , 10, e0142267	3.7	39
97	Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review. <i>Current Neuropharmacology</i> , 2015 , 13, 636-55	7.6	40
96	Early postnatal exposure to lithium in vitro induces changes in AMPAR mEPSCs and vesicular recycling at hippocampal glutamatergic synapses. 2015 , 40, 339-54		4
95	Sexual differences in long-term effects of prenatal chronic mild stress on anxiety-like behavior and stress-induced regional glutamate receptor expression in rat offspring. 2015 , 41, 80-91		19
94	Vitamin D3 Supplemental Treatment for Mania in Youth with Bipolar Spectrum Disorders. 2015 , 25, 415-24		24
93	Methamphetamine differentially affects BDNF and cell death factors in anatomically defined regions of the hippocampus. 2015 , 286, 97-108		41
92	Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. 2015 , 148, 114-31		821
91	A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts. 2016 , 12, 1687-703		50
90	Mitochondrial dysfunction in bipolar disorder: Evidence, pathophysiology and translational implications. 2016 , 68, 694-713		91
89	DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing. 2016 , 17, 202		16
88	Genetics of long-term treatment outcome in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016 , 65, 17-24	5.5	26
87	A model of the mitochondrial basis of bipolar disorder. 2017 , 74, 1-20		83
86	From direct to indirect lithium targets: a comprehensive review of omics data. 2017 , 9, 1326-1351		25
85	Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy. 2017 , 16, 176-186		24

84	Anterior Cingulate Cortex Glutamatergic Metabolites and Mood Stabilizers in Euthymic Bipolar I Disorder Patients: A Proton Magnetic Resonance Spectroscopy Study. 2018 , 3, 985-991		11
83	Excitatory and inhibitory synaptic dysfunction in mania: an emerging hypothesis from animal model studies. 2018 , 50, 1-11		25
82	Neuroprotective Strategies in Neonatal Brain Injury. 2018 , 192, 22-32		29
81	Neuroprotective effects of lithium: what are the implications in humans with neurodegenerative disorders?. <i>Psychologie & Neuropsychiatrie Du Vieillissement</i> , 2018 , 16, 78-86	0.3	7
80	Sodium Valproate Ameliorates Neuronal Apoptosis in a Kainic Acid Model of Epilepsy via Enhancing PKC-Dependent GABAR α Serine 327 Phosphorylation. <i>Neurochemical Research</i> , 2018 , 43, 2343-2352	4.6	16
79	Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington's disease. <i>Metabolic Brain Disease</i> , 2018 , 33, 1459-1470	3.9	30
78	Molecular Signatures of Lithium Treatment: Current Knowledge. <i>Pharmacopsychiatry</i> , 2018 , 51, 212-219	2	8
77	The Adaptogenic and Neuroprotective Properties of Lithium Ascorbate. <i>Neuroscience and Behavioral Physiology</i> , 2018 , 48, 409-415	0.3	1
76	Tualang Honey Reduced Neuroinflammation and Caspase-3 Activity in Rat Brain after Kainic Acid-Induced Status Epilepticus. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018 , 2018, 7287820	2.3	8
75	Free and Bound Therapeutic Lithium in Brain Signaling. <i>Accounts of Chemical Research</i> , 2019 , 52, 2960-2970	4.3	4
74	Combinational therapy of lithium and human neural stem cells in rat spinal cord contusion model. <i>Journal of Cellular Physiology</i> , 2019 , 234, 20742-20754	7	4
73	Pharmacologic Management of Patients with Neurologic Disorders. 2019 , 69-84		
72	Glycogen synthase kinase-3 inhibition as a potential pharmacological target for vascular dementia: In silico and in vivo evidence. <i>Computers in Biology and Medicine</i> , 2019 , 108, 305-316	7	5
71	Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	46
70	Contemporary Dental Pharmacology. 2019 ,		1
69	Glutamate-Related Antibodies and Peripheral Insulin-Like Growth Factor in Bipolar Disorder and Lithium Prophylaxis. <i>Neuropsychobiology</i> , 2019 , 77, 49-56	4	9
68	NO-sGC-cGMP signaling influence the anxiolytic like effect of lithium in mice in light and dark box and elevated plus maze. <i>Brain Research</i> , 2019 , 1704, 114-126	3.7	8
67	A Case-Control Study of Essential and Toxic Trace Elements and Minerals in Hair of 0-4-Year-Old Children with Cerebral Palsy. <i>Biological Trace Element Research</i> , 2020 , 195, 399-408	4.5	1

66	Antimania-Like Effect of Regulating the Glutamatergic Neurotransmission in REM-Sleep Deprivation Rats. <i>BioMed Research International</i> , 2020 , 2020, 3636874	3	1
65	Glycogen synthase kinase-3 signaling in cellular and behavioral responses to psychostimulant drugs. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020 , 1867, 118746	4.9	3
64	Novel Therapeutic Approach for the Management of Mood Disorders: In Vivo and In Vitro Effect of a Combination of L-Theanine, L. and Rehder & E.H. Wilson. <i>Nutrients</i> , 2020 , 12,	6.7	5
63	Hypothesis: bipolar disorder is an Epstein-Barr virus-driven chronic autoimmune disease - implications for immunotherapy. <i>Clinical and Translational Immunology</i> , 2020 , 9, e1116	6.8	1
62	Antidepressants and antipsychotics: anaesthetic implications. <i>Anaesthesia and Intensive Care Medicine</i> , 2020 , 21, 229-234	0.3	1
61	Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1103-1110	4	5
60	Preface. 2021 , xi-xii		
59	Brain Imaging and the Mechanisms of Antidepressant Action. 2021 , 248-260		
58	Brain Imaging of Reward Dysfunction in Unipolar and Bipolar Disorders. 2021 , 39-48		
57	Molecular Imaging of Dopamine and Antipsychotics in Bipolar Disorder. 2021 , 236-247		
56	Magnetoencephalography Studies in Mood Disorders. 2021 , 192-205		
55	Plate Section (PDF Only). 2021 , 283-286		
54	Functional Near-Infrared Spectroscopy Studies in Mood Disorders. 2021 , 166-174		
53	Mood Disorders. 2021 ,		
52	Neuroimaging Studies of Effects of Psychotherapy in Depression. 2021 , 261-272		
51	Neuroimaging Brain Inflammation in Mood Disorders. 2021 , 121-134		
50	An Overview of Machine Learning Applications in Mood Disorders. 2021 , 206-218		
49	Electrophysiological Biomarkers for Mood Disorders. 2021 , 175-191		1

48	Neuroanatomical Findings in Bipolar Disorder. 2021 , 16-27		
47	Imaging Glutamatergic and GABAergic Abnormalities in Mood Disorders. 2021 , 105-120		
46	Magnetic Resonance Spectroscopy Investigations of Bioenergy and Mitochondrial Function in Mood Disorders. 2021 , 83-104		
45	Brain Imaging Methods in Mood Disorders. 2021 , 1-6		
44	Effects of Lithium on Brain Structure in Bipolar Disorder. 2021 , 219-235		
43	Neuroprogression as an Illness Trajectory in Bipolar Disorder: A Selective Review of the Current Literature. <i>Brain Sciences</i> , 2021 , 11,	3-4	6
42	Mood Stabilizers in Psychiatric Disorders and Mechanisms Learnt from In Vitro Model Systems. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
41	Neuroimaging Biomarkers in Pediatric Mood Disorders. 2021 , 28-38		
40	Neuroanatomical Findings in Unipolar Depression and the Role of the Hippocampus. 2021 , 7-15		
39	Functional Connectome in Bipolar Disorder. 2021 , 59-82		
38	Resting-State Functional Connectivity in Unipolar Depression. 2021 , 49-58		
37	Imaging Genetic and Epigenetic Markers in Mood Disorders. 2021 , 135-150		
36	fMRI Neurofeedback as Treatment for Depression. 2021 , 151-165		
35	Hippocampal and prefrontal cortical NMDA receptors mediate the interactive effects of olanzapine and lithium in memory retention in rats: the involvement of CAMKII-CREB signaling pathways. <i>Psychopharmacology</i> , 2020 , 237, 1383-1396	4-7	4
34	Critical role for Annexin A7 in secondary brain injury mediated by its phosphorylation after experimental intracerebral hemorrhage in rats. <i>Neurobiology of Disease</i> , 2018 , 110, 82-92	7-5	14
33	Neurons derived from transplanted neural stem cells restore disrupted neuronal circuitry in a mouse model of spinal cord injury. <i>Journal of Clinical Investigation</i> , 2010 , 120, 3255-66	15-9	214
32	The host range of gammaretroviruses and gammaretroviral vectors includes post-mitotic neural cells. <i>PLoS ONE</i> , 2011 , 6, e18072	3-7	5
31	Valproate alters dopamine signaling in association with induction of Par-4 protein expression. <i>PLoS ONE</i> , 2012 , 7, e45618	3-7	15

30	[Adaptogenic and neuroprotective effects of lithium ascorbate]. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , 2016 , 116, 86-91	0.4	3
29	The role of CA1 CB1 receptors on lithium-induced spatial memory impairment in rats. <i>EXCLI Journal</i> , 2018 , 17, 916-934	2.4	6
28	Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models. <i>Current Neuropharmacology</i> , 2017 , 15, 815-830	7.6	22
27	Lithium: a potential estrogen signaling modulator. <i>Journal of Applied Biomedicine</i> , 2009 , 7, 175-188	0.6	3
26	The neuroprotective effect of treatment of valproic Acid in acute spinal cord injury. <i>Journal of Korean Neurosurgical Society</i> , 2012 , 51, 191-8	2.3	17
25	Neuroprotective action of lithium in disorders of the central nervous system. <i>Journal of Central South University (Medical Sciences)</i> , 2011 , 36, 461-76	0.4	25
24	Valproic acid neuroprotection in 6-OHDA lesioned rat, a model for parkinson's disease. <i>HOAJ Biology</i> , 2012 , 1, 4		12
23	Effects of Chronic and Acute Lithium Treatment on the Long-term Potentiation and Spatial Memory in Adult Rats. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019 , 17, 233-243	3.4	5
22	Neuroprotection against Apoptosis. 2003 , 145-154		
21	The ups and downs of lithium. 2003 ,		
20	Effects of lithium on gene expression. 2006 , 365-379		
19	Lithium and Its Role in Psychiatry. 2008 , 651-659		
18	Neuroprotective Agents in Mood Disorders: Pathophysiological and Therapeutic Implications. 2010 , 417-449		
17	Development of Brain Monoaminergic Systems. 2011 , 130-151		
16	Medikamente zur Behandlung bipolarer affektiver Störungen. 2012 , 629-657		1
15	[Neurotrophic effects of lithium stimulate the reduction of ischemic and neurodegenerative brain damage]. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , 2016 , 116, 99-108	0.4	0
14	Ouabain inhibitor rostafuroxin attenuates dextromethorphan-induced manic potential. <i>Food and Chemical Toxicology</i> , 2021 , 158, 112657	4.7	0
13	The underlying neurobiology of bipolar disorder. <i>World Psychiatry</i> , 2003 , 2, 136-46	14.4	91

12	Effects of mood stabilizers on DNA damage in an animal model of mania. <i>Journal of Psychiatry and Neuroscience</i> , 2008 , 33, 516-24	4.5	58
11	Mood stabilizer-regulated miRNAs in neuropsychiatric and neurodegenerative diseases: identifying associations and functions. <i>American Journal of Translational Research (discontinued)</i> , 2013 , 5, 450-64	3	27
10	Hormesis and neural stem cells. <i>Free Radical Biology and Medicine</i> , 2021 , 178, 314-314	7.8	7
9	Lithium and Erectile Dysfunction: An Overview.. <i>Cells</i> , 2022 , 11,	7.9	1
8	Phosphorylation of PI3K/Akt at Thr308, but not MAPK kinase, mediates lithium-induced neuroprotection against cerebral ischemia in mice.. <i>Experimental Neurology</i> , 2022 , 351, 113996	5.7	0
7	What lithium holds in epilepsy?. <i>Current Neuropharmacology</i> , 2022 ,	7.6	
6	Antidepressant chronotherapeutics normalizes prefrontal 1H-MRS glutamate in bipolar depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022 , 110606	5.5	0
5	On the role of glycogen synthase kinases in the molecular mechanisms of stress conditions and prospects for the use of lithium ascorbate. 2022 , 14, 60-68		0
4	Lithium Provides Broad Therapeutic Benefits in an Alzheimer's Disease Mouse Model. 2022 , 1-18		0
3	Does treatment with autophagy-enhancers and/or ROS-scavengers alleviate behavioral and neurochemical consequences of low-dose rotenone-induced mild mitochondrial dysfunction in mice?.		0
2	Does lithium attenuate the liver damage due to oxidative stress and liver glycogen depletion in experimental common bile duct obstruction?. 2023 , 466, 116489		0
1	Lithium in Cancer Therapy: Friend or Foe?. 2023 , 15, 1095		0